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ABSTRACT
Background. Optimization of the techniques and larger accessibility to mechanical reperfusion have 
significantly improved the outcomes of patients with ST-segment elevation myocardial infarction (STEMI). 
However, suboptimal results have been observed in certain higher-risk subsets of patients, as in advanced 
age, where the benefits of primary PCI are more debated.  We evaluated the impact of systematic primary 
percutaneous coronary intervention (PCI) and an optimized STEMI network on the long-term prognosis 
from a single centre experience. 
Methods. We included STEMI patients included in the FAST-STEMI network between 2016 and 2019. 
Ischemia duration was defined as the time from symptoms onset to coronary reopening (pain-to-balloon, 
PTB). The primary study endpoint (PE) was a composite of mortality and recurrent MI at long-term follow-up. 
Indywidual outcome endpoints were also assessed.
Results. We included 253 patients undergoing primary PCI and discharged alive. Mean age was 67.2 
± 12.5 years, 75.1% males and 19.8% diabetics. 
At a median follow-up of 581 [307–922] days, the primary endpoint occurred in 24 patients (7.9%), of 
whom 5.5% died.
The occurrence of a cardiovascular event was significantly associated with advanced age (p < 0.001), 
renal failure (p = 0.03), lower ejection fraction at discharge (p = 0.04) and longer in-hospital stay 
(p = 0.01).  The median PTB was 198 minutes [IQR: 125–340 min], that was significantly longer among 
patients experiencing the PE (p = 0.01).
A linear relationship was observed between age and PTB (r = 0.13, p = 0.009).
However, both age ≥ 75 years and PTB above the median emerged as independent predictors of the 
primary endpoint (age: HR [95%CI] = 5.56 [2.26–13.7], p < 0.001, PTB: HR [95%CI] = 3.59 [1.39–9.3], 
p = 0.01). Similar results were observed for overall mortality. 
Conclusion. The present study shows that among STEMI patients undergoing primary PCI in a single 
centre, the duration of ischemia and advance age are independently associated to long-term mortality and 
recurrent myocardial infarction. However, longer time to reperfusion was observed among elderly patients. 
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Background
Prompt restoration of coronary perfusion represents 
the pivotal treatment for patients with ST-segment myo-
cardial infarction (STEMI), allowing to improve myocar-
dial salvage and prognosis [1–3]. Primary percutaneous 
coronary intervention (PCI) has emerged in the last 
years as the strategy of choice for mechanical reperfu-
sion, therefore great efforts have been accomplished 
for improving the techniques and facilitating the access 
of STEMI patients to coronary revascularization [4, 5]. 
The optimization of the networks for transportation 
and the larger availability of primary-PCI facilities, in 
particular, have shortened the time to reperfusion and 
contributed to enlarge the indications to primary PCI 
even to those higher-risk subsets of patients, as the 
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elderly, that have been associated to an increased 
rate of complications and poorer outcomes [6–8]. 
Despite the role of a systematically invasive approach, 
rather than optimal medical therapy, has been largely 
debated among patients in advanced age or with se-
vere comorbidities, several studies have confirmed the 
prognostic benefits of early primary PCI even in these 
settings [9, 10]. 
Nevertheless, the predictors of recurrent ischemic 
events, complications and long-term outcomes in el-
derly and more critical subsets of STEMI patients still 
need to be focused into additional dedicated studies. 
Aim of the present study was to provide a single 
centre experience within an optimized STEMI network 
and a systematically invasive approach, attempting 
to define the predictors of the long term-prognosis 
among consecutive STEMI patients undergoing pri-
mary PCI. 
Methods
We analysed STEMI patients discharged alive after 
primary PCI in a non-academic public hospital from 
June 2016 to June 2019 and included in the FAST-
STEMI database.
For all patients, demographical data, clinical fea-
tures, cardiovascular risk factors and follow-up end-
points were derived from electronic medical reports. 
Data regarding the time of symptoms onset, medical 
contact, transportation, primary PCI, duration of hospi-
talization and ejection fraction at discharge were derived 
from the individual patients’ worksheets enclosed in 
the FAST-STEMI system, (wwww.sistemapiemonte.it), 
a regional network for the optimization and monitoring 
of the management of patients with STEMI. Ischemia 
duration was defined as the time from symptoms onset 
to primary PCI (pain-to-balloon, PTB). 
Outcome endpoints
The primary study endpoint (PE) was the occurrence 
of all-cause mortality or recurrent myocardial infarction 
at long-term follow-up. Secondary endpoints were the 
individual components of the primary endpoint or target 
vessel revascularization (TVR). 
Statistical analysis 
All statistical analyses were performed by SPSS Sta-
tistics Software 22.0 (IBM SPSS Inc., Chicago, Illinois). 
Continue variables were represented as mean ± SD, 
while categorical variables as percentage. Chi-Squared 
and paired ANOVA test were appropriately used to com-
pare continuous and categorical variables, respectively. 
In case of non-normal distribution median, IQR and non 
parametric U-test were applied. Linear regression anal-
ysis was applied to evaluate the relationship between 
continuous variables, as age and PTB.
Cox regression analysis and Kaplan-Meier survival 
curves were used to define the role of different variables 
on the PE. A p value < 0.05 was considered statistically 
significant.   
Results
We included 253 patients treated with primary PCI 
for STEMI and discharged alive. 
Baseline characteristics of the included patients are 
displayed in Table 1. Mean age was 67.2 ± 12.5 years, 
75.1% were males and 19.8% diabetics. 
At a median follow-up of 581 [307–922] days, the 
primary endpoint occurred in 24 patients (7.9%). The 
occurrence of a cardiovascular event was significant-
ly associated with advanced age (p < 0.001), renal 
failure (p = 0.03), lower ejection fraction at discharge 
(p = 0.04) and longer in-hospital stay (p = 0.01), as 
in Table 1. 
Mean times from symptoms onset to PCI are dis-
played in Table 2. In particular, PTB was significantly 
longer among patients experiencing the PE (p = 0.03) 
and also the percentage of patients with PTB above the 
median (198 minutes [IQR: 125–340 min]), (72.7% vs 
41.6%, p = 0.006, Fig. 1). 
A linear relationship was observed between age and 
PTB (r = 0.13, p = 0.009), as in Figure 2.
However, both age ≥ 75 years and PTB above the 
median emerged as independent predictors of the pri-
mary endpoint (age: HR [95%CI] = 5.56 [2.26–13.7], 
p < 0.001, PTB: HR [95%CI] = 3.59 [1.39–9.3], p=0.01). 
Kaplan Meier survival estimates in the overall popu-
lation and according to age and ischemia duration are 
displayed in Figure 3. 
Similar results were observed for the 14 patients 
(5.5%) that died at follow-up. In fact age ≥ 75 years 
and PTB above the median were confirmed as in-
dependent predictors of overall mortality (age: HR 
[95%CI] = 9.86 [2.15–45.3], p = 0.003, PTB: HR 
[95%CI] = 5.29 [1.15–24.3], p = 0.03).
Recurrent myocardial infarction was observed 
among 11 patients (4.3%) whereas 5 patients (2%) 
underwent target vessel revascularization. 
Discussion
The present manuscript provides a single centre 
experience on the prognostic predictors at long-term 
among STEMI patients treated in an updated network 
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Table 1. Clinical and demographic characteristics in the overall population and according to primary endpoint (PE)
Clinical features Overall
(n = 253)
PE
(n = 24)
No PE (n = 229) P Value
Male gender (%) 75.1 66.7 76 0.32
Age (mean ± SD) 67.2 ± 12.5 77.3 ± 10 66.1 ± 12.3 < 0.001
Age ≥ 85 years (%) 6.7 20.8 5.2 0.01
Age ≥ 75 years (%) 31.6 66.7 29.7 < 0.001
Diabetes mellitus (%) 19.8 16.7 20.1 0.99
Renal failure (%) 19.4 37.5 17.5 0.03
Transportation (%) 0.36
Primary ambulance transportation 45.8 58.1
Individual access 33.3 31.7
Other 20.9 10.2
Infarction location (%) 0.77
Anterior 49.4 55.6 48.8
Inferior 39.9 33.3 40.6
Other 10.7 11.1 10.6
Ejection fraction at discharge (mean ± SD) 51.8 ± 10.1 47.7 ± 13.5 52.2 ± 9.6 0.04
Table 2. Reperfusion timetable in the overall population and according to primary endpoint (PE)
STEMI network timetable 
(median [IQR])
Overall
n = 253
PE
(n = 24)
No PE 
(n = 229)
P Value
Pain to FMC (min) 97 [49–225] 150 [79–359] 90 [49–224] 0.22
First medical contact to door (min) 54 [36–90] 72.5 [39.5–128.8] 53 [36.5–87.5] 0.49
Pain to balloon (min) 198 [125–340] 257.5 [177.5–421.8] 180 [125–307] 0.013
Hospital stay (days) 5 [4–7] 6 [4–10.5] 5 [4–7] 0.15
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Figure 1. Bar graph showing the rate of patients with 
PTB above the median among event-free patients or 
experiencing the primary endpoint (PE)
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Figure 2. Linear relationship between age and  pain to 
balloon (PTB)
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In addition, the introduction of more potent anti-
thrombotic strategies have significantly lowered the 
rate of thrombotic complications and recurrent ischemic 
events [14, 15], although being weighted by a sig-
nificantly increased risk of bleedings, and especially 
among those more fragile subsets of patients, as the 
elderly, that are, often prevented from aggressive revas-
cularization strategies and newer antiplatelet agents for 
the fear of haemorrhagic complications [16].  
Recent trials and registries specific for patients in ad-
vanced age presenting with acute coronary syndromes 
have documented the overall superiority of an early 
invasive approach over a conservative one [9, 10, 17].
Nevertheless, elderly patients still continue to dis-
play suboptimal treatment and a worse prognosis, and 
especially in the setting of STEMI, where advanced age 
has been associated to a more delayed presentation, 
unsuccessful reperfusion and larger infact size, con-
ditioning survival and the risk of recurrent ischemic 
events [18, 19]. 
In fact, De Luca et al. have shown in a large cohort 
of over 1500 patients that advanced age was associated 
with a significantly higher clinical and angiographic risk 
profile, emerging as an independent predictor of 1-year 
mortality [20]. 
In addition, age and time to treatment have been 
related with a larger scintigraphic infact size, a param-
eter strictly associated with mortality, the duration of 
hospitalization and the risk of recurrent cardiovascular 
events [21, 22]. 
Large efforts have been accomplished so far in order 
to optimize the access of the patients to primary PCI 
facilities, including by the creation of joint networks, 
field in ambulance triage, for earlier activation of cath-
lab personnel and direct access of the patients without 
the emergency room passage [23–25].
In the Italian region of Piedmont, the FAST-STEMI 
network was created in 2011 in order to provide a geo-
graphical and logistic organization of the strategies for 
transferring patients with STEMI to primary-PCI capable 
hospital with the shortest transportation times. In-ambu-
lance ECG and its telematic transmission, the creation of 
operations centres and data collection and monitoring 
through a unique web-based database represented the 
major point of the FAST-STEMI project [26]. 
We present the experience of a single centre from 
a non-academic public hospital enclosed in the FAST-
STEMI network. We demonstrated a short time to reper-
fusion in our population as compared to the data from 
currently available literature, in line with the average 
reported at a regional and national level [27].  How-
ever, the patients experiencing the primary endpoint 
displayed a significantly longer duration of ischemia 
as compared to event-free patients, mainly driven by 
an almost double time from symptoms to diagnosis.
Figure 3. Kaplan Meier estimates for global survival in the 
overall population (3A) and according to age (3B) and pain 
to balloon (PTB) (3C)
and with systematic primary PCI. We demonstrated 
that advanced age and the duration of ischemia rep-
resented the most relevant determinants of mortality 
and recurrent myocardial infarction, therefore emerging 
as the most challenging situations to be addressed in 
future studies. 
Technological improvements and early reperfusion 
strategies have significantly contributed to increase the 
success of percutaneous coronary interventions (PCI) 
and ameliorated the outcomes of patients with acute 
myocardial infarction [11–13]. 
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Moreover, elderly patients experienced a longer time 
to treatment as compared to younger patients, however 
advanced age also emerged as an independent predic-
tor of the long-term outcomes. Indeed, more atypical 
symptoms, delayed presentation and the assessment 
of concomitant or pre-existing medical conditions have 
been previously established to prevent a prompt access 
of these patients to primary PCI. 
In fact, in the National Registry of Myocardial in-
farction (NRMI), chest pain at presentation occurred in 
89.9% of STEMI patients < 65 years versus 56.8% of 
those ≥ 85 years of age [28]. In the Global Registry of 
Acute Coronary Events (GRACE) registry, the median 
time from symptom onset to presentation was 2.3 hours 
in those under 45 years, but 3.0 hours over age 85 [29] 
and in the Cooperative Cardiovascular Project the pre-
dictors of late arrival (> 6 hours after symptom onset) 
included advanced age included advanced age and 
diabetes [30].
In our STEMI population, the time to reperfusion 
was shorter than in the GRACE registry [29] and older 
studies [31, 32], underlying the improvements provided 
by a dedicated optimized network. However, the dura-
tion of ischemia had a median of > 3 hours, that was 
therefore superior to the 120 minutes recommended 
in guidelines and reported by Brodie et al. [33] as the 
cut-off for achieving an improvement in left ventricular 
ejection fraction (6.9% at < 2 h vs 3.1% at > or = 2 h, 
p = 0.007), and in 30-days mortality.
Nevertheless, in a recent analysis from the large 
population based registry (ISACS-TC) consisting of 
2,730 clinically stable patients with STEMI presenting 
12–48 hours after symptom onset and treated with PCI 
or medical therapy, mortality benefits were observed 
among patients presenting ≥ 25–48 hours after symptom 
onset, and especially for patients ≥ 65 years old [34]. 
In addition, our definition of the primary endpoint 
also included recurrent myocardial infarction, that was 
associated with a higher patient’s risk profile, although 
the lower number of events did not allow to perform an 
independent evaluation as an outcomes endpoint. In 
fact, previous studies have shown that rehospitaliza-
tions after MI are most frequently attributed to bleeding 
(24.5%), infections (14.3%), and cancer (9.1%), with 
age emerging as the main independent predictor of 
unplanned hospitalization [35]. 
However, Verdoia et al. also reported enhanced 
platelet reactivity and suboptimal response to antiplate-
let drugs among patients in advanced age, potentially 
increasing the risk of stent thrombosis and recurrent 
ischemic events [36].
Therefore, further efforts should be accomplished in 
order to improve the management of patients admitted 
with STEMI, shortening the duration of ischemia and 
optimizing the reperfusion strategies and especially 
among those higher-risk subsets of patients as the 
elderly, where future dedicated studies are certain-
ly warranted.
Limitations
A first limitation can be considered the small sample 
of patients included in our study, thus potentially affect-
ing the statistical power of our study. However, our study 
represents a common scenario from a real life public 
hospital and furthermore, our results are in line with the 
conclusions reached in far larger cohorts of patients. 
Another limitation can be considered the lack of 
certain information about clinical and procedural fea-
tures and on pharmacological therapy at discharge. 
However, these data were not considered in the work-
sheets of the FAST-STEMI database, that represented 
the primary source of our analysis. Nevertheless, our 
population was managed according to the best stan-
dard of care in terms of drug-eluting stent technologies, 
dual antiplatelet therapy and medications, as statins 
and beta-blockers. 
Finally, our data are derived from a single centre 
and limited to a  quite elderly population in specific 
geographic environment, thus limiting the generability 
of our results. 
Conclusion 
The present study shows that among STEMI patients 
undergoing primary PCI in a single centre, the duration 
of ischemia and advance age are independently asso-
ciated to long-term mortality and recurrent myocardial 
infarction. However, longer time to reperfusion was 
observed among elderly patients.
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